Journal List > Prog Med Phys > v.29(4) > 1126765

Koo, Chung, Chung, Jin, and Kim: Feasibility Assessment of Physical Factors of Rectal Cancer Short-Course Chemoradiotherapy with Delayed Surgery

Abstract

To verify the correlations between the clinical outcomes and physical factors of short-course chemoradiotherapy (SCRT) and long-course chemoradiotherapy (LCRT) with delayed surgery in patients with rectal cancer. Seventy-two patients with rectal cancer were enrolled in this study. Nineteen patients were treated with SCRT (25 Gy, 5 fractions) by intensity-modulated radiation therapy (IMRT), and 53 patients were treated with LCRT (50.4 Gy, 28 fractions) by three-dimensional conformal radiation therapy (3DCRT). Various physical factors for the target and organs at risk (OARs) were calculated to compare the clinical outcomes. The organ equivalent dose (OED) and lifetime attributable risk (LAR) of bowels and bladders were similar between the SCRT and LCRT groups, whereas the values of femurs were higher in the LCRT group. The equivalent uniform dose and normal tissue complication probability were higher in the LCRT than the SCRT group for most organs. Treatment complications, including anastomotic leakage, bowel adhesion, and hematologic toxicity, were not significantly different between SCRT and LCRT groups. CIs were 0.84±0.2 and 0.61±0.1 for SCRT and LCRT, respectively. The CVIs were 1.07±0.0 and 1.10±0.1, and the HIs were 0.09±0.0 and 0.11±0.1 for SCRT and LCRT, respectively. The sphincter-saving rates were 89.5% and 94.3% for SCRT and LCRT, respectively. The complete pathologic remission rates were 21.1% and 13.2%, and the down-staging rates were 47.4% and 26.4% for SCRT and LCRT, respectively. SCRT with IMRT is comparable to conventional LCRT in both physical indexes and clinical outcome. The preoperative SCRT, compensated by IMRT, is an effective and safe modality.

REFERENCES

1.Graf W., Dahlberg M., Osman MM., Holmberg L., Pahlman L., Glimelius B. Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol. 1997. 43:133–7.
crossref
2.Ngan SY., Burmeister B., Fisher RJ., Solomon M., Goldstein D., Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012. 30:3827–33.
crossref
3.Van den Bent MJ., Afra D., de Witte O., Ben Hassel M., Schraub S., Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005. 366:985–90.
crossref
4.Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004. 351:1731–40.
crossref
5.Chung M., Kim D., Chung W., Lee S., Jeong S., Hwang J, et al. Preoperative short-vs. long-course chemoradiotherapy with delayed surgery for locally advanced rectal cancer. Oncotarget. 2016.
6.Glimelius B. Rectal cancer irradiation. Long course, short course or something else? Acta Oncol. 2006. 45:1013–7.
7.Bosset JF., Collette L., Calais G., Mineur L., Maingon P., Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006. 355:1114–23.
crossref
8.Radu C., Berglund A., Pahlman L., Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol. 2008. 87:343–9.
crossref
9.Mu X., Lofroth PO., Karlsson M., Zackrisson B. The effect of fraction time in intensity modulated radiotherapy: theoretical and experimental evaluation of an optimisation problem. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2003. 68:181–7.
crossref
10.Fenkell L., Kaminsky I., Breen S., Huang S., Van Prooijen M., Ringash J. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2008. 89:287–91.
crossref
11.Arbea L., Ramos LI., Martinez-Monge R., Moreno M., Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiation oncology. 2010. 5:17.
crossref
12.Luxton G., Hancock SL., Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. International journal of radiation oncology, biology, physics. 2004. 59:267–84.
crossref
13.Fenoglietto P., Laliberte B., Allaw A., Ailleres N., Idri K., Hay MH, et al. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2008. 88:77–87.
crossref
14.W.H.O.Life Expectancy at Birth (years). 2015.
15.E.P.A.EPA Radiogenic Cancer Risk Models and Projections for the U.S. Population. 2008.
16.Brodin NP., Munck Af Rosenschold P., Aznar MC., Kiil-Berthelsen A., Vogelius IR., Nilsson P, et al. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol. 2011. 50:806–16.
crossref
17.Kim DW., Chung WK., Yoon M. Imaging doses and secondary cancer risk from kilovoltage cone-beam CT in radiation therapy. Health physics. 2013. 104:499–503.
crossref
18.Surveillance, Epidemiology, and End Results (SEER).
19.National Research Council of the National Academies. Health risks from exposure to low levels of ionizing radiation, BEIR VII Phase 2. 2006 (Washington DC: The national Academic Press).
20.Sun Young Moon MY., Chung Weon Kuu., Chung Mijoo., Shin Dong Oh., Kim Dong Wook. Comparison of Dosimetric Parameters of Patient with Large and Pendulous Breast Receiving Breast Radiotherapy in the Prone versus Supine Position. Prog Med Phys. 2015. 26:7.
21.Emami B., Lyman J., Brown A., Coia L., Goitein M., Munzen-rider JE, et al. Tolerance of normal tissue to therapeutic irradiation. International journal of radiation oncology, biology, physics. 1991. 21:109–22.
crossref

Table 1.
Patient and treatment plan characteristics.
Factor Short course (n=19) Long course (n=53)
Age
  <70 5 (m=73.7) 12 (m=76.8)
  ≥70 14 (m=58.3) 41 (m=57.6)
Prescribed dose
  Gy 25 50.4
BED
  Gy 150 141
Dose per fraction
  Gy 5 1.8
Normalization
  % 96 96
PTV
  Volume (cm3) 1109 985
  D98 (%) 95 93
  D50 (%) 100 100
  D2 (%) 104 104

LAR, lifetime attributable risk; OED, organ equivalent dose; m mean value; PTV, planning target volume; D98/50/2, dose covering 98%/50%/2% of PTV; BED, Biologically effective dose.

Table 2.
Dosimetric factors and clinical outcomes according to radiation group.
factor Short course (n=19) Long course (n=53) P
LAR
  Bladder 4E+02 4E+02 0.294
  Bowel 3E+02 3E+02 0.248
  LT Femur 15.45 21.89 0.235
  RT Femur 15.07 21.76 0.235
OED
  Bladder 2.E-01 2.E-01 0.303
  Bowel 1E-01 1E-01 0.242
  LT Femur 0.45 0.64 0.235
  RT Femur 0.44 0.64 0.235
EUD (Gy)
  Bladder 26.75 27.83 0.248
  Bowel 5.59 4.47 0.254
  LT Femur 17.51 22.84 0.236
  RT Femur 17.05 22.26 0.241
NTCP (%)
  Bladder 5E-07 6E-06 0.305
  Bowel 5E-13 1E-10 0.241
  LT Femur 8E-09 5E-05 0.357
  RT Femur 4E-09 4E-06 0.280
CI
  PTV 0.84 0.61 0.302
CVI      
  PTV 1.10 1.07 0.415
HI
  PTV 0.09 0.11 0.645
Local recurrence     0.442
  Yes 1 12  
  No 18 41  
Complete remission     0.465
  Yes 4 7  
  No 15 46  
Distant metastasis     0.162
  Yes 1 12  
  No 18 41  

LAR, lifetime attributable risk; OED, organ equivalent dose; EUD, effective uniform dose; NTCP, normal tissue complication probability; CI, conformity index; CVI, coverage index; HI, homogeneity index.

Table 3.
Toxicities according to radiation group.
  Short course (n=19) Long course (n=53) P
Grade 3, 4 Grade 3, 4
Leakage 3 (21.1) 5 (9.4) 0.353
Hematology 1 (5.3) 0 (0.0) 0.391
Adhesion 1 (5.3) 1 (1.9) 0.168

Data are presented as n (%).

TOOLS
Similar articles